This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Carlo and Baker cover the latest developments after a devastating tornado outbreak over the weekend, plus an eye on Omicron and inflation, and not even Spielberg can save the box office.
Reusable rocket developer Stoke Space Technologies raised $65 million in a Series A round led by Breakthrough Energy Ventures, a firm founded by Bill Gates. Stoke says its reusable rockets provide the satellite industry with low-cost, on-demand access to and from orbit. As companies like SpacX and Blue Origin are also making commitments to rocket reusability, Stoke says it is taking a different approach with a system designed to be 100% reusable, comprised of rockets designed to fly daily, like an airplane. Stoke co-founder and CEO Andy Lapsa joins Cheddar News' Closing Bell to discuss.
Humans are set to return to a place we have not been in nearly 50 years: the moon. NASA's Artemis program is expected to have astronauts back on the lunar surface by 2025. NASA says it will use what it learns on the moon to take the next giant leap - sending the first astronauts to Mars. The Artemis program also includes contributions from private companies like SpaceX, as well as academic research institutions like Georgia Tech. Georgia Tech professor of practice and former NASA astronaut Sandra Magnus joins Future of Space: Humankind's Leap Forward to discuss.
The CDC warns that COVID-19 is rapidly spreading with Omicron variant cases doubling every two days in the United States. How do current vaccines hold up against the new strain, and what does it mean for your upcoming holiday travel? Cheddar News breaks things down with infectious diseases specialist Dr. William Schaffner of Vanderbilt University School of Medicine.
President Joe Biden is expected to meet with his COVID-19 response team as the omicron variant continues to surge across the country. Experts say Delta is driving this surge but Dr. Anthony Fauci says Omicron will take over. Emergency physician Dr. Daniel Fagbuyi joins Cheddar News to discuss.
Omicron is on course to become the dominant COVID strain in the U.S., even as Delta is causing another spike in cases. According to Johns Hopkins University data, cases across the country are up 40% from last month, with New York City as a major hotspot. Outbreaks are now causing Broadway performances to be canceled, colleges and universities to shift to online classes, sports leagues to postpone games, and more. Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to discuss the surge in cases and how we can best protect ourselves against the new variant.
